Brit J Heamatol: Clinical Outcome of T-Cell Large Particle Lymphocytic Leukemia

T-cell large granulele leukemia (T-LGLL) is an incurable form of leukemia characterized by abnormal cytotoxic T-cell cloning proliferation, which can lead to severe neutrophil reduction, blood transfusion-dependent anemia and whole blood cell reductionThe most commonly used drugs for the disease include methotrexate (MTX), cyclophosphamide (Cy) and cyclosporine, which can be partially alleviated (PR) and rarely completely alleviated (CR), researchers evaluated the clinical course and treatment response of 60 patients with t-LGLL in a continuous consultation to assess clinical outcomes and potential future treatment outcomes, according to a study published recently in the journal British Journal of Blood System Diseasesmale patients, patients with elevated lactic acid dehydrogenase, and patients without rheumatoid arthritis had overall survival impairmentCy is the most effective second-line drug with a total remission rate of 70% (ORR; three CRs, four PRRs)All patients with failed first-line MTX treatment are effective for second-line Cy treatmentIn relapsed or Cy refractive cases, the ORRs of alensalmone (n-4) and spray statins (n-3) were 50% and 66% respectively, while a patient treated with Duvelisib received a long-term responsein this large-scale retrospective analysis, the results of this study show that Cy is an effective treatment for second-line therapy in T-LGLL patients and should be considered as a candidate for pre-treatment in some high-risk patientsFor patients with recurrent/refractive T-LGLL, prospective studies are needed to evaluate the efficacy of statins, alensonesapositive, and new drugs such as Duvelisib